A Randomized, Double Blind, Placebo-controlled Study to Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

Trial Profile

A Randomized, Double Blind, Placebo-controlled Study to Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs GSK 2245035 (Primary)
  • Indications Allergic asthma; Allergic rhinitis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2014 Planned End Date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top